HIGHLIGHTS
QGel™ in Nature
26.11.09, London. QGel™ technology is featured in a review article of the highly reputed journal Nature. The article, entitled
Designing materials to direct stem-cell fate, critically reviews the state-of-the-art of current biomaterials being developed to serve as powerful artificial microenvironments to study stem-cell fate both in culture and in vivo. The article argues that the synergy between cell biological technologies and biomaterials, such as QGel™, promises to have a profound impact on stem-cell biology that will advance stem-cell-based clinical approaches to tissue regeneration.
QGel at ESB2009
07.09.09, Lausanne. QGel™ was at the
22nd European Conference on Biomaterials. Many scientists interested in QGel™ technology came to visit our booth in the Exhibitor's Hall where they obtained information on upcoming QGel products. If you would like to join our mailing list please fill out the form by clicking here.
LATEST NEWS
Webinar A : Getting started with QGel™ 19.05.11, Lausanne. QGel™ is holding a webinar series for scientists using QGel™ and would like to learn more details on how to plan and successfully execute experiments with QGel™ products. More information about QGel™ webinars on the Webinar page.
QGel™ at AACR 2011 03.04.11, Orlando. QGel™ is exhibiting at the 102nd Annual Meeting of the American Association for Cancer Research (AACR). "The AACR congress attracts over 6000 leading scientists and is considered the most important cancer research meeting in the world.", says Colin Sanctuary, CEO of QGel™, "This venue is an excellent opportunity for QGel™ to present QGel™ matrix ability to grow efficiently cancer cells as spheroids in 3D." To download product information please visit QGel™ Support page.
QGel™ at ASCB 2010 11.12.10, Philadelphia. QGel™ is exhibiting at the American Society for Cell Biology (ASCB) Annual Meeting. "The ASCB is the premier society for over 10'000 world class scientists.", says Colin Sanctuary, CEO of QGel™, "Being present at this venue will give our customers the opportunity to learn more about our synthetic 3D Matrix for cell culture." To download product information please visit the Support section on the QGel™ website.
QGel™ at ISSCR 15.06.10, San Francisco. QGel™ is exhibiting at the International Society for Stem Cell Research Annual Meeting. "Several QGel™ customers are attending this international event", says Colin Sanctuary, CEO of QGel™, "offering an excellent opportunity for us to spread the word on QGel™ technology." To download product information please visit the Support section on the QGel™ website.
QGel™ Delivers 01.06.10, Lausanne. Since the launch of QGel™ in April, first customers have used QGel™ to grow cells in 3D for a number of different cell lines. "Over the past weeks, QGel™ has been used to grow stem cells and cancer cells in 3D at world-class institutes around the globe", says Colin Sanctuary, CEO of QGel™, "and our customers are excited with their first results." Customer projects include growing mini-tumours in QGel™ to screen certain drug candidates, stem cell expansion in a 3D environment and delivery of rhBMP-2 for bone regeneration . To download product information please visit the Support section on the QGel website.
QGel™ MT 3D Matrix Launched
21.04.10, Seattle. QGel SA announced today the official launch of its QGel™ MT 3D Matrix product, a novel hydrogel material to culture cells in 3D and grow tissue, at the Society for Biomaterials 2010 Annual Meeting being held in Seattle. A fully synthetic 3D matrix, QGel's product is delivered as a dry powder in a small vial; after adding a special liquid solution containing cells, the dry powder reacts within a few minutes to form a gel, thus encapsulating the cells in 3D. The cells in the gel can be incubated and observed clearly for months using standard laboratory techniques, and later analysed using standard life sciences analytical methods. For additional information please visit the Product Information section on the QGel website.
C. Gandar joins QGel team 16.11.09, Ecublens. Ms. Gandar, a bioengineer with expertise in hydrogel matrix technology, joined QGel SA and will provide support in product development as well as take charge of some key marketing projects. Ms. Gandar obtained a Master in Bioengineering and Biotechnology at the EPFL and completed her Master's thesis using QGel™ technology at the Health Sciences and Technology of the Harvard-MIT division.
QGel supported by Canton de Vaud 10.10.09, Ecublens. QGel SA obtains official support from the SELT, a section of the government Department of Economy of the State of Vaud, Switzerland (DEC) that aims to predict, and develop the necessary infrastructural support to ensure the continued successful development of the Vaud economy. The SELT provides resources and financial support to companies to help them establish their activity in the Vaud region. By offering this aid, the SELT encourage economic development through the creation of jobs, and increased overall quality of life in Vaud. QGel SA warmly thanks the DEC and the SELT for their support to the establishment of QGel SA, as well as recognizing that QGel SA has strong potential to contribute to the future economic well-being of the Canton de Vaud, Switzerland.
Dr. Rizzi to Lead Development 01.09.09, Ecublens. Simone Rizzi, expert
in hydrogel matrix technology, joined QGel SA and will lead activities in Business and Product Development. After completing his PhD in 2004 under the guidance of Professor Jeffrey Hubbell , Dr. Rizzi conducted hydrogel development work at Institut Straumann , and complemented his expertise as a post doctoral research fellow at the Queensland University of Technology.
Dr. Sanctuary appointed as CEO 01.07.09, Ecublens. QGel SA was incorporated in July 2009 and Dr. Colin Sanctuary was appointed as Chief Executive Officer by the Board of Directors to oversee the establishment of the company. Dr. Sanctuary obtained his PhD in 2003 and was trained in business management at the IMD. After completing his PhD, Dr. Sanctuary has held various management positions starting at Institut Straumann where, as Product Manager, he was globally responsible for regenerative products. Dr. Sanctuary joins QGel SA from Medtronic where he most recently managed the biologics product portfolio in Europe; this included the bone growth factor rhBMP-2 product.
